
$8.5 Bn Epigenetics Markets, 2021-2024 & 2025-2029 - Increasing Investment in Biomedical Research, Trends Towards Precision Medicine, Growing Interest in Liquid Biopsy - ResearchAndMarkets.com
The "Epigenetics Market" report has been added to ResearchAndMarkets.com's offering.
The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.
This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) inhibitors.
Epigenetics is the study of heritable changes in gene expression or activity that do not involve alterations to the DNA sequence itself. The global market for epigenetics research tools and reagents by study method was estimated at $1.8 billion in 2023. This market should reach $2.2 billion by the end of 2029, growing at a CAGR of 4.1% through the forecast period. The demand for new research tools remains constant as scientists strive to advance understanding and pursue groundbreaking discoveries.
The mounting clinical evidence supporting the relevance of epigenetics in various diseases has fueled a surge in epigenetic research, thereby increasing the demand for high-quality reagents and research tools. The trend is expected to continue over the forecast period, yielding market growth.
Epigenetic therapeutics target and modulate epigenetic mechanisms to restore a more normal epigenomic configuration. The global market for epigenetic therapeutics market by drug class targeting DNMT, IDH, HDAC and EZH2 was estimated at $938.2 million in 2023. The market is expected to reach $1.9 billion by the end of 2029, growing at a CAGR of 11% over the forecast period. Emerging research demonstrates the potential of epigenetics-based therapeutics as a versatile and targeted treatment modality, offering a viable alternative to conventional chemotherapy. Scientific advances, the growing number of cancer patients and the unmet need in oncology are key growth factors of the epigenetic drugs market.
The report includes:
- Analyses of the trends in global markets for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region
- Facts and figures pertaining to the market dynamics, technological advancements, regulatory landscape, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Evaluation of recent patent activity and key granted and published patents in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Bristol-Myers Squibb Co., Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific Inc., and Qiagen
Company Profiles
- Active Motif Inc.
- Bio-Rad Laboratories Inc.
- Bio-Techne
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- Exact Sciences Corp.
- Guardant Health
- Hologic Inc.
- Les Laboratoires Servier
- Merck KGaA
- Nucleix
- Promega Corp.
- Qiagen
- Revvity Inc. (Perkinelmer)
- Thermo Fisher Scientific Inc.
Key Attributes:
Report Attribute | Details |
No. of Pages | 115 |
Forecast Period | 2024 - 2029 |
Estimated Market Value (USD) in 2024 | $4.8 Billion |
Forecasted Market Value (USD) by 2029 | $8.5 Billion |
Compound Annual Growth Rate | 11.8% |
Regions Covered | Global |
Key Topics Covered:
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Epigenetics Overview
- DNA Methylation
- Histone Modification
- RNA Modifications
- Epigenetic Modulators
Chapter 3 Market Dynamics
- Market Dynamics Snapshot
- Market Drivers
- Rising Prevalence of Cancer and Unmet Need in Oncology
- Advances in Analytical Technologies and Tools
- Increasing Investment in Biomedical Research
- Trend Towards Precision Medicine
- Growing Interest in Liquid Biopsy
- Market Restraints
- From Bench to Bedside: The Translation Gap in Epigenetics
- Epigenetic Therapeutics: Limited Clinical Success Against Solid Tumors
- Stringent Regulatory Landscape
- Market Trends
- Combining Epigenetic Modifiers with Other Therapeutic Class
- Multi-omics Integration
- Long-Read Sequencing in Epigenetic Research
- Epigenetic Biomarkers-based Blood Test for Cancer Screening
Chapter 4 Emerging Technologies and Developments
- Emerging Technologies
- Epigenome Editing
- Epitranscriptomics
- Bromodomain and Extra-Terminal Domain Inhibitors
- Menin Inhibitors
- Application Beyond Oncology
- Pipeline Analysis
- Overview
- Novel Epigenetic Therapeutics in Development in Phase 2 and Above
Chapter 5 Market Segmentation Analysis
- Segmentation Breakdown
- Epigenetics Research Tools and Reagents Market, by Study Method
- Market Overview
- Market Size and Forecast
- DNA Methylation
- Histone Modification
- RNA Modification
- In Vitro Diagnostics (IVDs) Market, by Clinical Indication
- Market Overview
- Market Size and Forecast
- Epigenetic Therapeutics Market, by Drug Class
- Market Overview
- Market Size and Forecast
- Geographic Breakdown
- Epigenetics Research Tools and Reagents Market, by Region
- Market Size and Forecast
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 Competitive Intelligence
- Research Tools and Reagents
- In Vitro Diagnostics
- Therapeutics
Chapter 7 Sustainability in the Epigenetics Market: An ESG Perspective
- Introduction to ESG
- Key ESG Issues in Epigenetics Pharmaceuticals and Diagnostics Market
- Sustainability Practices in Pharmaceuticals Manufacturing
- Sustainable Packaging
- Key ESG Issues in Epigenetics Research Tools Market
- ESG Risk Ratings Score -- Understanding the Data
- Concluding Remarks
Chapter 8 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/uggn6b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250523984908/en/

Distribution channels:
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release